**Core Concept**
Sugammadex is a selective relaxant binding agent (SRBA) that specifically encapsulates and inactivates rocuronium and vecuronium, two long-acting non-depolarizing neuromuscular blockers (NMBs). This unique mechanism allows for rapid reversal of neuromuscular blockade.

**Why the Correct Answer is Right**
Sugammadex works by encapsulating the benzylisoquinolinium ring of rocuronium and vecuronium, thereby preventing them from interacting with the nicotinic acetylcholine receptor (nAChR) at the neuromuscular junction. This encapsulation leads to a significant decrease in the concentration of free rocuronium and vecuronium, allowing for rapid recovery from neuromuscular blockade. The selective binding of sugammadex to these NMBs makes it an effective and efficient reversal agent.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because sugammadex is not a competitive antagonist of acetylcholine at the neuromuscular junction, but rather a selective binder of rocuronium and vecuronium.
**Option B:** This option is incorrect because sugammadex does not act through the breakdown of rocuronium and vecuronium by enzymes such as esterases or amidases.
**Option C:** This option is incorrect because sugammadex does not have a direct effect on the nicotinic acetylcholine receptor (nAChR) itself, but rather on the NMBs that interact with the receptor.

**Clinical Pearl / High-Yield Fact**
Sugammadex is a valuable addition to the reversal of neuromuscular blockade, particularly in situations where rapid recovery is critical, such as in patients undergoing laparoscopic surgery. Its unique mechanism of action allows for a more efficient and effective reversal of long-acting NMBs.

**Correct Answer: D. Sugammadex is a selective relaxant binding agent (SRBA) that encapsulates and inactivates rocuronium and vecuronium.**